MNLO Menlo Therapeutics Inc.

8.19
+0.9  (+12%)
Previous Close 7.29
Open 7.3
Price To Book 1.3
Market Cap 190271587
Shares 23,232,184
Volume 73,069
Short Ratio
Av. Daily Volume 100,601

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released December 10, 2018 - primary endpoint met. Presentation of data March 2, 2019 1pm at American Academy of Dermatology Annual Meeting. Phase 3 planned for 2019.
Serlopitant
Pruritus associated with psoriasis
Phase 3 data due 1H 2020.
Serlopitant
Pruritus associated with prurigo nodularis
Phase 2 data released October 8, 2018. Endpoints not met.
Serlopitant
Refractory chronic cough
Phase 2 data released April 9, 2018. Endpoints not met.
Serlopitant
Pruritus associated with atopic dermatitis

Latest News

  1. Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting
  2. Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019
  3. Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis
  4. Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation
  5. What does Menlo Therapeutics Inc.’s (NASDAQ:MNLO) Balance Sheet Tell Us About Its Future?
  6. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  7. Lawsuit for Investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) announced by Shareholders Foundation
  8. Menlo Therapeutics Inc. (MNLO): Are Hedge Funds Right About This Stock?
  9. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  10. Robbins Arroyo LLP: Menlo Therapeutics Inc. (MNLO) Misled Shareholders According to Class Action
  11. Market Trends Toward New Normal in Apptio, Menlo Therapeutics, Tanger Factory Outlet Centers, Cedar Realty Trust, Toll Brothers, and II-VI — Emerging Consolidated Expectations, Analyst Ratings
  12. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.
  13. Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
  14. This year's Bay Area IPO batch remains up 44% despite market turbulence
  15. Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International — Future Expectations, Projections Moving into 2018
  16. INVESTOR ALERT: Kaskela Law LLC Announces Investigation of Menlo Therapeutics Inc. on Behalf of Investors - MNLO
  17. Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Seaboard, Menlo, Super Micro, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm